Grover disease is a benign but at times severely pruritic and treatment-refractory inflammatory disease that primarily affects older adults. The pathophysiology is poorly understood. It has been associated with medications, including chemotherapeutics, but most commonly occurs without a medication trigger.1-3 Furthermore, it is found to coexist with other chronic dermatoses, such as atopic dermatitis, contact dermatitis, and xerosis.4 With an association and phenotypic overlap with atopic disease, we hypothesized that dupilumab (interleukin [IL]-4/13 blockade) might be clinically beneficial to patients with severe Grover disease.